Cancer Immunotherapy

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.

• 1. TNFR2 in cancer immunology and immunotherapyXin Chen2. From the Hellstrom paradox towards cancer cureIngegerd Hellstrom and Karl Erik Hellstrom3. CAR T-cell treatment of T-cell malignancy Martin Pule4. Immunotherapy of pancreatic cancerJorg Kleeff5. Cancer stem cell immunology/immunotherapy Federica Cavallo6. Cytokine release syndromeAlexander Shimabukuro-Vornhagen7. Tumor Cell-Based Mechanisms of Resistance to Immune AttackLouis M. Weiner8. Mushroom compounds in cancer immunotherapyPeter Amwoga Ayeka